Core Viewpoint - Merck & Co., Inc. is facing a class action lawsuit from investors due to a significant drop in stock price following the company's announcement that it would not meet its projected 11billionrevenuefromGardasilsalesby2030[1][4].Group1:ClassActionDetails−TheclassactionrepresentsinvestorswhopurchasedMercksecuritiesbetweenFebruary3,2022,andFebruary3,2025,withadeadlinetofilealeadplaintiffmotionbyApril14,2025[1].−InvestorsareencouragedtocontactthePortnoyLawFirmforacomplimentarycaseevaluationandtodiscusstheirlegalrights[2].Group2:FinancialProjectionsandImpact−ThecomplainthighlightsthatMerckhadprojected11 billion in revenue from Gardasil sales by 2030, supported by optimistic forecasts regarding demand in China [3]. - On February 4, 2025, Merck announced it would halt Gardasil shipments to China, leading to a stock price drop from 99.79to90.74 per share, a decline of over 9% in one day [4].